Lisata Therapeutics entered into a Merger Agreement with Kuva Labs Inc. and its subsidiary Kuva Acquisition Corp. for a tender offer to acquire all common shares at $5.00 per share in cash plus one non-tradeable CVR for a potential $1.00 milestone payment tied to certepetide regulatory filing. The Company Board unanimously approved and recommends stockholders tender their shares.
Key takeaways
Merger Agreement dated March 6, 2026 with Kuva Labs Inc. (Parent) and Kuva Acquisition Corp. (Purchaser)
Tender offer for all common shares at $5.00 cash per share + 1 CVR
CVR milestone: $1.00 cash if NDA or equivalent filed/accepted for certepetide product by 7th anniversary of Closing or CVR termination
Preferred shares convert at $0.0005 per share
Minimum tender condition: majority of outstanding shares
Transaction expected to close Q2 2026; no financing condition